Literature DB >> 28361861

Diagnostic challenges with intraoral myeloid sarcoma: report of two cases & review of world literature.

P Kumar1, H Singh1, N Khurana2, A B Urs1, J Augustine1, R Tomar2.   

Abstract

BACKGROUND: Myeloid sarcomas (MS) are rare extramedullary tumors composed of blasts of myeloid lineage that either precede, follow or present concomitantly with acute myeloid leukaemia (AML) or myeloproliferative neoplasms. The diagnosis of MS is especially challenging in patients without an antecedent history of leukemia.
METHODS: We present 2 cases of intraoral MS that presented as de novo lesions. A detailed review of cases of intraoral MS that either preceded or presented along with leukemia has been done with emphasis on diagnostic criteria used.
RESULTS: Two male patients aged 28 and 5 years presented with MS with one patient presenting with concomitant AML. A combination of morphological and immunohistochemical methods was used for diagnosis. A thorough review of world literature revealed 44 cases of intraoral MS that presented as de novo lesions.
CONCLUSION: Intraoral MS is a rare tumor with poor prognosis. It may be diagnostically challenging due to its protean clinical manifestations and histological overlap with other tumors.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28361861

Source DB:  PubMed          Journal:  Exp Oncol        ISSN: 1812-9269


  2 in total

1.  Myeloid sarcoma of the oral cavity: A case report and review of 89 cases from the literature.

Authors:  Bruno-Augusto-Benevenuto de Andrade; Renan-de Barros Farneze; Michelle Agostini; Ellen-Brilhante Cortezzi; Aline-Corrêa Abrahão; Marcia-Grillo Cabral; Alicia Rumayor; Mário-José Romañach
Journal:  J Clin Exp Dent       Date:  2017-09-01

Review 2.  Clinical characteristics and management of primary granulocytic sarcoma of the oral cavity: A case report and literature review.

Authors:  Yun-Gang Hu; Xiao-Hua Deng; Wei Lei; Xiao-Lin Li
Journal:  Medicine (Baltimore)       Date:  2020-10-23       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.